Reversible Smad-dependent signaling between tumor suppression and oncogenesis

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Cancer cells often evade tumor suppression by manipulating transforming growth factor-beta (TGF-beta) signaling.
• The precise molecular mechanisms underlying TGF-beta pathway dysregulation in cancer, particularly in Ras-transformed cells, are not fully understood.

Purpose of the Study:

• To elucidate the distinct roles of TGF-beta receptor I (TbetaRI)-mediated and c-Jun NH2-terminal kinase (JNK)-mediated Smad phosphorylation in Ras-driven oncogenesis.
• To investigate whether targeting specific Smad phosphorylation events can restore tumor suppression and inhibit invasion in Ras-transformed cancer cells.

Main Methods:

• Utilized Ras-transformed cell models to study TGF-beta signaling.
• Investigated the phosphorylation status of Smad2 and Smad3 at the COOH-terminal (pSmad2/3C) and linker regions (pSmad2/3L) using Western blotting and other molecular biology techniques.
• Employed a mutant Smad3 lacking JNK-dependent phosphorylation sites to selectively block linker phosphorylation.

Main Results:

• Ras transformation suppresses TbetaRI-dependent pSmad3C signaling, leading to c-Myc downregulation and reduced growth inhibition.
• Hyperactive Ras constitutively activates JNK-mediated pSmad2/3L signaling, promoting tumor invasion through upregulation of plasminogen activator inhibitor-1, MMP-1, MMP-2, and MMP-9.
• Selective blockade of JNK-dependent linker phosphorylation in Smad3 preserved tumor-suppressive pSmad3C signaling and abrogated the invasive phenotype in Ras-transformed cells.

Conclusions:

• Ras-transformed cells exhibit a switch in Smad signaling, favoring oncogenic invasion over tumor suppression.
• Targeting the JNK/pSmad2/3L pathway offers a potential therapeutic strategy to shift Smad signaling from oncogenesis back to tumor suppression, thereby inhibiting cancer progression.